Astex – Oncology and CNS Drug Discovery & Development

Committed to the fight against cancer and CNS disorders

Committed to the fight against cancer and CNS disorders

World leading innovative drug discovery & development

Our research and development teams utilize our cutting edge technology platform in the relentless pursuit of innovative solutions that address the extensive and complex challenges in oncology and diseases of the CNS.

Astex has built a rich product portfolio with multiple drugs in clinical development

Latest from Astex

11 February 2020

Astex Pharmaceuticals announces U.S. Food and Drug Administration (FDA) acceptance for review of an NDA for the combination oral hypomethylating agent cedazuridine and decitabine (ASTX727 or oral C-DEC), for the treatment of MDS and CMML

9 December 2019

Astex Pharmaceuticals presents topline data from the ASCERTAIN phase 3 study of its novel, oral hypomethylating agent cedazuridine and decitabine (ASTX727) in MDS and CMML at the American Society of Hematology Meeting in Orlando, FL.

In The News

14 May 2020
Astex CSO, David Rees, elected as new Fellow of the Academy of Medical Sciences

Sustaining innovation

Innovative postdoctoral research fellowships

Learn more

Career Opportunities

We seek to attract and retain talented individuals who are passionate about improving patient outcomes.

Committed to the fight against cancer and CNS disorders

Committed to the fight against cancer and CNS disorders

World leading innovative drug discovery & development

Astex has built a rich product portfolio with multiple drugs in clinical development

Latest from Astex

In The News

Sustaining innovation

Career Opportunities

Useful links